<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Drug discovery guided by maximum drug likeness - Health AI Hub</title>
    <meta name="description" content="To overcome the high attrition rate and limited clinical translatability in drug discovery, we introduce the concept of Maximum Drug-Likeness (MDL) and develop ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Drug discovery guided by maximum drug likeness</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.21895v1" target="_blank">2512.21895v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-26
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Hao-Yu Zhu, Shi-Jie Du, Lu Xu, Wei Shi
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.QM
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.21895v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.21895v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">To overcome the high attrition rate and limited clinical translatability in drug discovery, we introduce the concept of Maximum Drug-Likeness (MDL) and develop an applicable Fivefold MDL strategy (5F-MDL) to reshape the screening paradigm. The 5F-MDL strategy integrates an ensemble of 33 deep learni...</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Medical/health related research</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper describes an AI-driven platform that integrates an ensemble of 33 deep learning sub-models to construct a 33-dimensional property spectrum. This AI system quantifies the global phenotypic alignment of candidate molecules with clinically approved drugs, guiding the prioritization of high-potential molecules for drug discovery, specifically targeting drug-resistant bacteria. This is a clear application of AI in accelerating and optimizing the medical drug discovery process.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>See abstract for details</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>See paper for methodology</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>See abstract</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>Potential clinical applications</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not analyzed</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not analyzed</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">q-bio.QM</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">q-bio.QM</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">To overcome the high attrition rate and limited clinical translatability in drug discovery, we introduce the concept of Maximum Drug-Likeness (MDL) and develop an applicable Fivefold MDL strategy (5F-MDL) to reshape the screening paradigm. The 5F-MDL strategy integrates an ensemble of 33 deep learning sub-models to construct a 33-dimensional property spectrum that quantifies the global phenotypic alignment of candidate molecules with clinically approved drugs along five axes: physicochemical properties, pharmacokinetics, efficacy, safety, and stability. Using drug-likeness scores derived from this 33-dimensional profile, we prioritized 15 high-potential molecules from a 16-million-molecule library. Experimental validation demonstrated that the lead compound M2 not only exhibits potent antibacterial activity, with a minimum inhibitory concentration (MIC) of 25.6 ug/mL, but also achieves binding stability superior to cefuroxime, as indicated by Molecular Mechanics Poisson-Boltzmann surface area (MM-PBSA) calculations of -38.54 kcal/mol and a root-mean-square deviation (RMSD) of 2.8 A. This strategy could overcome scaffold constraints and offers an efficient route for discovering lead compounds with favorable prospects against drug-resistant bacteria.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>46 pages,8 figures, 5 tables</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>